Capstone Targets Positive EBITDA Run-Rate in Q2 2026

Reuters

Jan 21

Capstone Targets Positive EBITDA Run-Rate in <a href="https://laohu8.com/S/QTWO">Q2</a> 2026

Capstone Therapeutics Corporation has announced a significant cost rationalization program, eliminating approximately $2.0 million in annualized corporate overhead expenses effective immediately. The company expects these measures to materially improve its financial performance, with management targeting a positive EBITDA run-rate beginning in the second quarter of 2026, independent of revenue growth. The impact of these cost reductions will begin to be reflected in the first quarter and become clear by the quarter ending June 30, 2026. The CEO has also reduced his annual cash salary to $1.00 to align executive compensation with shareholder equity appreciation. Capstone plans to release an earnings power presentation in early February outlining a range of EBITDA expectations under various macroeconomic assumptions.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Capstone Therapeutics Corporation published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1129547) on January 21, 2026, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2605016511"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2605016511\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2605016511?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-21 20:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2605016511","market":"fut","top_or_hot":-1,"title":"Capstone Targets Positive EBITDA Run-Rate in Q2 2026","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Capstone Targets Positive EBITDA Run-Rate in <a href=\"https://laohu8.com/S/QTWO\">Q2</a> 2026\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Capstone <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Corporation has announced a significant cost rationalization program, eliminating approximately $2.0 million in annualized corporate overhead expenses effective immediately. The company expects these measures to materially improve its financial performance, with management targeting a positive EBITDA run-rate beginning in the second quarter of 2026, independent of revenue growth. The impact of these cost reductions will begin to be reflected in the first quarter and become clear by the quarter ending June 30, 2026. The CEO has also reduced his annual cash salary to $1.00 to align executive compensation with shareholder equity appreciation. Capstone plans to release an earnings power presentation in early February outlining a range of EBITDA expectations under various macroeconomic assumptions.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Capstone Therapeutics Corporation published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1129547) on January 21, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Capstone Targets Positive EBITDA Run-Rate in Q2 2026</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCapstone Targets Positive EBITDA Run-Rate in Q2 2026\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-01-21 20:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Capstone Targets Positive EBITDA Run-Rate in <a href=\"https://laohu8.com/S/QTWO\">Q2</a> 2026\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Capstone <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Corporation has announced a significant cost rationalization program, eliminating approximately $2.0 million in annualized corporate overhead expenses effective immediately. The company expects these measures to materially improve its financial performance, with management targeting a positive EBITDA run-rate beginning in the second quarter of 2026, independent of revenue growth. The impact of these cost reductions will begin to be reflected in the first quarter and become clear by the quarter ending June 30, 2026. The CEO has also reduced his annual cash salary to $1.00 to align executive compensation with shareholder equity appreciation. Capstone plans to release an earnings power presentation in early February outlining a range of EBITDA expectations under various macroeconomic assumptions.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Capstone Therapeutics Corporation published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1129547) on January 21, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CAPS","symbol_name":"Capstone Holding Corp","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260121:nNDL58Vj6K:1","article_id":"2605016511","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2605016511","pubTimestamp":1768996871,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Capstone Therapeutics Corporation has announced a significant cost rationalization program, eliminating approximately $2.0 million in annualized corporate overhead expenses effective immediately. The company expects these measures to materially improve its financial performance, with management targeting a positive EBITDA run-rate beginning in the second quarter of 2026, independent of revenue growth. The impact of these cost reductions will begin to be reflected in the first quarter and become clear by the quarter ending June 30, 2026. The CEO has also reduced his annual cash salary to $1.00 to align executive compensation with shareholder equity appreciation. Capstone plans to release an earnings power presentation in early February outlining a range of EBITDA expectations under various macroeconomic assumptions.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"CAPS":"Capstone Holding Corp","BK4139":"生物科技","BK4104":"贸易公司与经销商"},"translate_title":"Capstone的目标是2026年第二季度实现正EBITDA运行率","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CAPS":0.9},"content_text":"Capstone Targets Positive EBITDA Run-Rate in Q2 2026\n    \n\n        Capstone Therapeutics Corporation has announced a significant cost rationalization program, eliminating approximately $2.0 million in annualized corporate overhead expenses effective immediately. The company expects these measures to materially improve its financial performance, with management targeting a positive EBITDA run-rate beginning in the second quarter of 2026, independent of revenue growth. The impact of these cost reductions will begin to be reflected in the first quarter and become clear by the quarter ending June 30, 2026. The CEO has also reduced his annual cash salary to $1.00 to align executive compensation with shareholder equity appreciation. Capstone plans to release an earnings power presentation in early February outlining a range of EBITDA expectations under various macroeconomic assumptions.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Capstone Therapeutics Corporation published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1129547) on January 21, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}